AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.01 USD
+0.04 (1.35%)
Updated Jul 22, 2024 04:00 PM ET
Pre-Market: $3.00 -0.01 (-0.33%) 9:14 AM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABCL 3.01 +0.04(1.35%)
Will ABCL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for ABCL
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
TD Cowen Reaffirms Their Buy Rating on AbCellera Biologics (ABCL)
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%